Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%

Moderna Inc MRNA and Merck & Co Inc MRK announced distant metastasis-free survival (DMFS) results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study of mRNA-4157 (V940) plus Keytruda for resected high-risk melanoma.
The candidate is an investigational individualized neoantigen therapy.
The companies recently announced the first presentation of the study's primary endpoint, recurrence-free survival, from the Phase 2 KEYNOTE-942/mRNA-4157-P201 trial in April 2023 at the American Association for Cancer Research Annual Meeting.
mRNA-4157 (V940) plus Keytruda demonstrated a statistically significant and clinically meaningful improvement in DMFS, compared with Keytruda.
The combo therapy reduced the risk of developing distant metastasis or death by 65%.
Data from an exploratory subgroup analysis evaluating minimal residual disease (MRD) by circulating tumor DNA (ctDNA) as a biomarker of RFS were also presented.
Most ctDNA-evaluable patients were ctDNA-negative at baseline (88.0%, n=110/125), compared to ctDNA-positive patients at baseline (12.0%, n=15/125).
In ctDNA-negative patients at baseline, RFS was higher with mRNA-4157 (V940) in combination with Keytruda versus Keytruda alone, representing a 78% reduction in recurrence or death.
A similar trend was observed for ctDNA-positive patients.
However, the small sample size of the ctDNA subgroups limits the interpretation of these results.
The association between MRD patterns and mRNA-4157 (V940) treatment effect will be further explored in upcoming planned studies.
Price Action: MRNA shares are down 1.04% at $129.15, and MRK shares are up 0.49% at $113.07 on the last check Monday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga